Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. Read the press release here: https://bit.ly/3Ad5jXP
Actinium Pharmaceuticals, Inc.
Biotechnology Research
New York, NY 12,797 followers
Targeted Therapies for Patients with Unmet Needs
About us
Actinium Pharmaceuticals (NYSE: ATNM) is focused on developing innovative targeted radioimmunotherapies for the treatment of advanced cancers. Currently Investigating therapies in #AML and #BMT
- Website
-
http://www.actiniumpharma.com
External link for Actinium Pharmaceuticals, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- New York, NY
- Type
- Public Company
- Founded
- 2000
- Specialties
- Myeloablation, Hematopoeitic Stem Cell and Bone Marrow Transplant, Biopharmaceuticals and ADC's, Acute Myeloid Leukemia, and Multiple Myeloma
Locations
-
Primary
Actinium Pharmaceuticals
275 Madison Avenue, Suite 702
New York, NY 1001, US
Employees at Actinium Pharmaceuticals, Inc.
-
Paul Diamond
Vice President, Patent and Legal Counsel at Actinium Pharmaceuticals, Inc.
-
Steve Dressel
Biotech Executive | Finance & Operations | Biotech Growth Specialist | Vice President, Finance @ Actinium Pharmaceuticals
-
Gary Siegel
-
William van der Touw
Senior Vice President, Research & Development
Updates
-
Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted #Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications. Read the press release here: https://bit.ly/3A2I02C #CARTcelltherapy #CellTherapy
Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications :: Actinium Pharmaceuticals, Inc. (ATNM)
ir.actiniumpharma.com
-
Actinium (NYSE: ATNM) Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for #SickleCellDisease Patients Undergoing #BoneMarrowTransplant in Collaboration with Columbia University. Read the press release here: https://bit.ly/3A8BnvC #BMT
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University :: Actinium Pharmaceuticals, Inc. (ATNM)
ir.actiniumpharma.com
-
Actinium Pharmaceuticals (NYSE: ATNM) to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US. Read the press release here: https://bit.ly/3YfmQZ9 #Radiotherapy
Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US :: Actinium Pharmaceuticals, Inc. (ATNM)
ir.actiniumpharma.com
-
#EHA2024 recap: Abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium's ARC Actimab-A in acute myeloid leukemia (AML) models. Results available here: https://bit.ly/3VJRDLX
-
#EHA2024 presentation recap: median overall survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic #bonemarrowtransplant compared to 1.66 months in patients that did not receive Iomab-B in Phase 3 SIERRA Trial. More details here: https://lnkd.in/gBJF3HT3
-
Actimab-A is an ARC comprised of a CD33 targeting monoclonal antibody conjugated with the alpha-particle emitter Actinium-225 isotope payload. Read recent data presented at #SNMMI24 as we advance our Actimab program: https://bit.ly/3Ro0ikZ
-
Actinium recently announced the long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the Phase 3 SIERRA trial. Read more here: https://bit.ly/3VqCTQL #Oncology #EHA2024 #Radiotherapies
-
Actinium's Proprietary Linker Technology #SNMMI24 presentation recap: Evaluation of novel DOTA-based linkers for improved targeted #radiotherapy delivery to solid tumors. Details: https://bit.ly/3Rpk8vV
-
Actinium (NYSE: ATNM) Highlights Oral Presentation at #EHA2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial. Read the press release here: https://bit.ly/3VqCTQL #BMT